Magrath George, the Chief Executive Officer of Opus Genetics, Inc., has executed a sale of 28,258 shares of the company’s common stock. This transaction, reported on November 5, 2026, was necessary to fulfill tax withholding obligations associated with the vesting and settlement of restricted stock units.

This sale is significant as it underscores the financial dynamics within Opus Genetics, particularly in the context of the pharmaceutical preparations industry. The transaction occurred on November 3, 2026, and the shares were sold at a weighted average price of $3.8992, with individual sale prices ranging from $3.89 to $3.935.

Background

Opus Genetics, Inc. is a company focused on pharmaceutical preparations, operating under the SIC code 2834. The firm is incorporated in Delaware and is based in Durham, North Carolina. The company has undergone several name changes in its history, previously known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.

What the Filing Says

The filing indicates that the shares sold were part of an automatic transaction required by the issuer to manage tax obligations. As stated in the filing, “The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units.” This highlights that the sale was not a discretionary move by George.

Impact

This transaction may affect various stakeholders, including shareholders and potential investors, as it reflects the company's financial management strategies. The automatic nature of the sale may provide reassurance to investors that the CEO is complying with tax regulations rather than making speculative trades.

What's Next

The filing does not say what happens next.